Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / A real-world, observational study of erenumab for migraine prevention in Canadian patients.

< BACK TO ARCHIVE


Papers: 9 Apr 2022 - 15 Apr 2022


Human Studies


2022 Apr 10


Headache


http://www.ncbi.nlm.nih.gov/pubmed/35403223?dopt=Abstract

A real-world, observational study of erenumab for migraine prevention in Canadian patients.

Authors

A real-world, observational study of erenumab for migraine prevention in Canadian patients.
Becker WJ, Spacey S, Leroux E, Giammarco R, Gladstone J, Christie S, Akaberi A, Power SG, Minhas JK, Mancini J, Rochdi D, Filiz A, Bastien N
Headache. 2022 Apr 10.
PMID: 35403223.

Abstract

To assess real-world effectiveness, safety, and usage of erenumab in Canadian patients with episodic and chronic migraine with prior ineffective prophylactic treatments.
Read This Paper